Table 1 Baseline characteristics of study subjects according to incident diabetes.

From: The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea

 

Control (N = 4,021,636)

Diabetes (N = 1,005,409)

p value

Age (years)

57.2 ± 12.5

57.2 ± 12.5

1

  30–39

322,396 (8.0)

80,599 (8.0)

 

  40–64

2,500,100 (62.2)

625,025 (62.2)

 

  ≥65

1,199,140 (29.8)

299,785 (29.8)

 

Sex, male (%)

2,236,900 (55.6)

559,225 (55.6)

1

Comorbidities

  Hypertension (%)

1,021,775 (25.4)

523,654 (52.1)

<0.001

  Dyslipidemia (%)

490,804 (12.2)

432,661 (43.0)

<0.001

  Stroke (%)

137,904 (3.4)

71,141(7.1)

<0.001

  Myocardial infarction (%)

27,944 (0.7)

21,921 (2.2)

<0.001

  TIA (%)

36,794 (0.9)

18,046 (1.8)

<0.001

  Chronic pancreatitis (%)

6,648 (0.2)

8,186 (0.8)

<0.001

  Acute pancreatitis (%)

19,825 (0.5)

20,221 (2.0)

<0.001

  Hepatitis B (%)

66,873 (1.7)

39,675 (4.0)

<0.001

  Hepatitis C (%)

21,822 (0.5)

19,584 (2.0)

<0.001

  Biliary disease (%)

53,835 (1.3)

36,706 (3.7)

<0.001

  Alcoholism (%)

73,946 (1.8)

70,491 (7.0)

<0.001

  NAFLD (%)

401,238 (10.0)

333,593 (33.2)

<0.001

Place of residence

  

<0.001

  Urban

1,834,944 (45.6)

448,736 (44.6)

 

  Rural

2,186,692 (54.4)

556,673 (55.4)

 

Income status (%)

  

<0.001

  Quartile 1

960,140 (23.9)

247,883 (24.7)

 

  Quartile 2

870,293 (21.6)

218,062 (21.7)

 

  Quartile 3

938,082 (23.3)

227,968 (22.7)

 

  Quartile 4

1,086,158 (27.0)

247,814 (24.7)

 

Medical aid

166,963 (4.2)

63,682 (6.3)

 

Year of index date

  

1

  2009

1,009,616 (25.1)

252,404 (25.1)

 

  2010

994,300 (24.7)

248,575 (24.7)

 

  2011

1,042,652 (25.9)

260,663 (25.9)

 

  2012

975,068 (24.3)

243,767 (24.3)

 
  1. Data are presented as mean ± standard deviation, or number (%).
  2. The Student’s t-test or chi-squared test was used to compare the characteristics of the study participants at baseline.
  3. Abbreviations: TIA, transient ischemic attack; NAFLD, non-alcoholic fatty liver disease.